Iran Press/Iran news: Minoo Mohraz said on Monday that this vaccine's human trial has different phases and it will be injected to 56 people in the first phase.
She explained that the vaccine is given twice to these people; The first vaccine injected produces antibodies in the body after a while, but the main antibody that creates immunity is produced after the second injection.
Mohraz noted that the Iranian vaccine company's actions have been registered with the Food and Drug Administration (FDA) and the World Health Organization (WHO). Without FDA permission, a new phase of the vaccine would not have been possible.
If the test is successful and gets a manufacturing license from the FDA, it looks like the vaccine will enter the domestic market by late spring, the official stated.
Until the domestic vaccine is made, it is necessary to prepare imported vaccines, and the relevant authorities are working hard to achieve this, she noted.
Noting that two of the vaccines have been approved up to now, she said: "We are having some trouble buying vaccines due to US sanctions, but the government is following up."
She stressed that vaccines should now be available for high-risk groups and medical staff, such as nurses and physicians who deal directly with patients.
Mohracoroz had previously announced that the number of candidates for the COVID vaccine human trial in the country is high. People can only participate if they are completely healthy, have not contracted COVID-19, and are between 18 to 50 years old.
According to her, the candidates participating in this trial will be covered by insurance and given a gift.
104/221
Read More:
Medical Services to HIV patients free in Iran
Iran to produce medicine for Covid-19 by plasma-derived therapy
US intervention impedes Iran’s right to health, worsens coronavirus crisis: observers
Regional cooperation could be effective dealing with Coronavirus: Spox
